thymidine has been researched along with Carcinoma, Non-Small Cell Lung in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate the utility of plasma pharmacokinetic and pharmacodynamic measures including plasma deoxynucleosides, homocysteine and methylmalonic acid concentrations in understanding the time course and extent of the inhibition of thymidylate synthase (TS) by pemetrexed in the context of a phase I/II combination study with vinorelbine." | 2.73 | Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. ( Clarke, SJ; Li, KM; Rivory, LP, 2007) |
| "Thymidine was converted to its 3',5'-O-bis-tetrahydropyranyl ether, which was then converted to the N(3)-ethyl and propyl-substituted mesylate precursors." | 1.35 | N(3)-Substituted thymidine analogues V: synthesis and preliminary PET imaging of N(3)-[(18)F]fluoroethyl thymidine and N(3)-[(18)F]fluoropropyl thymidine. ( Alauddin, MM; Flores, LG; Gelovani, JG; Mukhopadhyay, U; Shavrin, A; Soghomonyan, S; Volgin, AY; Yeh, HH, 2008) |
| "We have compared the ability of cancer tissue to proliferate in native-state culture to the stage and histological grade of four major types of human carcinomas: breast, ovarian, colon, and lung." | 1.28 | Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage. ( Bordin, GM; Connors, KM; Hoffman, RM; Robb, JA; Umbreit, JN; Vescio, RA; Youngkin, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 10 (37.04) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Long, F | 1 |
| Li, Z | 1 |
| Wei, Z | 1 |
| Xie, Y | 1 |
| Chen, X | 2 |
| Yang, Y | 2 |
| Katz, SI | 2 |
| Lee, SJ | 2 |
| Yeo, JS | 1 |
| Lee, HJ | 2 |
| Lee, EJ | 1 |
| Kim, SY | 3 |
| Jang, SJ | 1 |
| Lee, JJ | 1 |
| Ryu, JS | 2 |
| Moon, DH | 2 |
| Lee, JS | 1 |
| Kang, JH | 1 |
| Lee, SH | 1 |
| Lee, CH | 1 |
| Son, J | 1 |
| Berger, I | 1 |
| Khalid, U | 1 |
| Patel, A | 1 |
| Cai, J | 1 |
| Farwell, MD | 1 |
| Langer, C | 1 |
| Aggarwal, C | 1 |
| Albelda, SM | 1 |
| Mukhopadhyay, U | 1 |
| Soghomonyan, S | 1 |
| Yeh, HH | 1 |
| Flores, LG | 1 |
| Shavrin, A | 1 |
| Volgin, AY | 1 |
| Gelovani, JG | 1 |
| Alauddin, MM | 1 |
| Yannelli, JR | 1 |
| Tucker, JA | 1 |
| Hidalgo, G | 1 |
| Perkins, S | 1 |
| Kryscio, R | 1 |
| Hirschowitz, EA | 1 |
| Mileshkin, L | 1 |
| Hicks, RJ | 1 |
| Hughes, BG | 1 |
| Mitchell, PL | 1 |
| Charu, V | 1 |
| Gitlitz, BJ | 1 |
| Macfarlane, D | 1 |
| Solomon, B | 1 |
| Amler, LC | 1 |
| Yu, W | 1 |
| Pirzkall, A | 1 |
| Fine, BM | 1 |
| Minamimoto, R | 1 |
| Toyohara, J | 1 |
| Seike, A | 1 |
| Ito, H | 1 |
| Endo, H | 1 |
| Morooka, M | 1 |
| Nakajima, K | 1 |
| Mitsumoto, T | 1 |
| Ito, K | 1 |
| Okasaki, M | 1 |
| Ishiwata, K | 1 |
| Kubota, K | 1 |
| Kim, EJ | 1 |
| Oh, SJ | 1 |
| Ahn, JH | 1 |
| Kim, SW | 1 |
| Yokoi, S | 1 |
| Yasui, K | 1 |
| Iizasa, T | 1 |
| Takahashi, T | 1 |
| Fujisawa, T | 1 |
| Inazawa, J | 1 |
| Zhou, J | 1 |
| Chen, J | 1 |
| Mokotoff, M | 1 |
| Zhong, R | 1 |
| Shultz, LD | 1 |
| Ball, ED | 1 |
| Senogles, SE | 1 |
| Brockenbrough, JS | 1 |
| Rasey, JS | 1 |
| Grierson, JR | 1 |
| Wiens, LW | 1 |
| Vesselle, H | 1 |
| Li, KM | 1 |
| Rivory, LP | 1 |
| Clarke, SJ | 1 |
| Favoni, RE | 1 |
| Ravera, F | 1 |
| Pirani, P | 1 |
| Ardizzoni, A | 2 |
| Noonan, D | 1 |
| de Cupis, A | 1 |
| Matturri, L | 1 |
| Lavezzi, AM | 1 |
| Grignani, F | 1 |
| Salomoni, G | 1 |
| Roviaro, GC | 1 |
| Maruno, K | 1 |
| Said, SI | 1 |
| Bihl, M | 1 |
| Tamm, M | 1 |
| Nauck, M | 1 |
| Wieland, H | 1 |
| Perruchoud, AP | 1 |
| Roth, M | 1 |
| Lokshin, A | 1 |
| Peng, X | 1 |
| Campbell, PG | 1 |
| Barsouk, A | 1 |
| Levitt, ML | 1 |
| Smith, PG | 1 |
| Marshman, E | 1 |
| Calvert, AH | 1 |
| Newell, DR | 1 |
| Curtin, NJ | 1 |
| Boehle, AS | 1 |
| Kurdow, R | 1 |
| Schulze, M | 1 |
| Kliche, U | 1 |
| Sipos, B | 1 |
| Soondrum, K | 1 |
| Ebrahimnejad, A | 1 |
| Dohrmann, P | 1 |
| Kalthoff, H | 1 |
| Henne-Bruns, D | 1 |
| Neumaier, M | 1 |
| Volm, M | 1 |
| Mattern, J | 1 |
| Samsel, B | 1 |
| Seigneurin, D | 1 |
| Guillaud, P | 1 |
| Vescio, RA | 1 |
| Connors, KM | 1 |
| Youngkin, T | 1 |
| Bordin, GM | 1 |
| Robb, JA | 1 |
| Umbreit, JN | 1 |
| Hoffman, RM | 1 |
| Alama, A | 1 |
| Costantini, M | 1 |
| Repetto, L | 1 |
| Conte, PF | 1 |
| Serrano, J | 1 |
| Nicolin, A | 1 |
| Barbieri, F | 1 |
| Bruzzi, P | 1 |
| Fox, NE | 1 |
| Twentyman, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?[NCT02069418] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-02-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thymidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
[Ki-67 antigen, a cell cycle and tumor growth marker].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Flow Cytometry; G1 Phase; Human | 1991 |
3 trials available for thymidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochl | 2011 |
4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Biological Transport; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; | 2012 |
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small- | 2007 |
23 other studies available for thymidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Circular RNA circ_0007841 participates in progression of nonsmall cell lung cancer via miR-199a-5p/SphK2 axis.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Humans; Lung Neoplasms; Mice; MicroRNAs | 2022 |
Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Enzyme Inhibitors; Humans; Lung Neoplasms | 2018 |
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Topics: Adult; Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dideoxynucleosi | 2014 |
Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Glutaminase; Humans; Lung Neoplasms; Thymidine | 2016 |
Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, An | 2017 |
N(3)-Substituted thymidine analogues V: synthesis and preliminary PET imaging of N(3)-[(18)F]fluoroethyl thymidine and N(3)-[(18)F]fluoropropyl thymidine.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Metabolic Clearance Rate; Mice; M | 2008 |
Characteristics of PBMC obtained from leukapheresis products and tumor biopsies of patients with non-small cell lung cancer.
Topics: Biopsy; Carcinoma, Non-Small-Cell Lung; Cytokines; Dendritic Cells; Humans; Immune System; Immunothe | 2009 |
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell P | 2013 |
Down-regulation of SKP2 induces apoptosis in lung-cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 3; Caspases; Cell Cycle; C | 2003 |
Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Blotting, Western; Body Weight; Bombesin; Carcinoma, Non-Small-Cell | 2003 |
D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
Topics: Bromocriptine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Dop | 2007 |
A simple quantitative assay for the activity of thymidine kinase 1 in solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Humans; Lung Neoplasms; Neoplasm Proteins; Radiopha | 2007 |
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines.
Topics: Adenocarcinoma; Binding, Competitive; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell | 1994 |
The prognostic value of cell proliferation in non-small cell lung cancer assessed with tritiated thymidine and anti-PCNA antibodies.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Survival; Humans; Lung Neoplasms; Prognosis; Pro | 1994 |
VIP inhibits the proliferation of small-cell and nonsmall-cell lung carcinoma.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Count; Cell Division; Cell Line | 1996 |
Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6.
Topics: Antibodies; Antisense Elements (Genetics); Blood Proteins; Carcinoma, Non-Small-Cell Lung; Cell Divi | 1998 |
Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Cell Division; Dime | 1999 |
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Division; Dipyridamole; Enzyme | 1999 |
Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line; Cell Movement; Cell Su | 2001 |
Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Carcinoma, Non-Small-C | 1992 |
Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Colonic Neoplasms; DNA Replication; Female; Humans; L | 1990 |
Thymidine labelling index as prognostic factor in resected non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Female; Humans; Lung Neoplasms; Male; Mi | 1990 |
A comparison of clonogenic and radionuclide uptake assays for determining the radiation response of human small-cell lung cancer xenografts and cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line; Cell Survival; Dose-Response Relat | 1987 |